Bleeding Disorders Treatment Market Overview
MRFR/Market Research Future projects the bleeding disorders treatment market to secure a decent CAGR of 10.0% between 2018 and 2023.
Growth Boosters and Deterrents
The American Society of Hematology reveals that in the year 2016, close to 20,000 Americans had hemophilia, with the prevalence higher in males. Hemophilia is a type of bleeding disorder that is rare and has been escalating at an alarming rate worldwide. Meanwhile, the burden of von Willebrand disease has been growing rapidly as well, emerging as one of the most common bleeding disorders in the United States resulting from clotting proteins. The disease affects both females and males and is prevalent in roughly 1% of the United States’ population. The Centers for Disease Control and Prevention also provides statistics that state that close to 400 newborns in the US every year, suffer from hemophilia.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6592
The bleeding disorder treatment industry is largely bolstered by the expanding patient pool, mounting awareness about the available treatment options, and the supportive compensation policies. Expiry of patents belonging to major brands can also present opportunities to generic drug manufacturers to make their foray into the bleeding disorder therapeutics market. the demand for bleeding disorder treatment options is quite robust in western economies in Europe and North America, in view of the exorbitant rates of the branded drugs. The demand for low-priced drugs is growing in developing and underdeveloped countries, given the reduced purchasing capacity of the patients in terms of medical treatment.
The competitive nature of the bleeding disorders treatment market is quite intense. Technological advances are the norm in the global market, with players increasingly churning out new and more innovative devices, solutions and therapies that facilitate effective treatment. To cite an instance, in December 2021, Takeda Pharmaceutical Company Limited launched myPKFiT, an advanced software as well as mobile app recently given the FDA approval. This software primarily caters to patients suffering from hemophilia A and are receiving treatment using ADYNOVATE. The company’s key aim is to offer effective hemophilia treatment while personalization remains the main focus.
Bleeding Disorders Treatment Market Segmentation
Bleeding disorders treatment industry can be categorized into type, drug class, treatment and end users.
The various types of bleeding disorders are hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and more.
Depending on drug class, the global market has been considered for global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market and plasma-derived coagulation factor concentrates market.
The different treatment options available in the market include hormone replacement therapy, desmopressin (DDAVP), anti-fibrinolytic/clot-stabilizing drugs, contraceptives, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials) and fibrin sealants.
Major end users in the global industry are clinics, hospitals, research institutes, specialty clinics, and others.
Bleeding Disorders Treatment Market Regional Insight
The regions across which the global market is spread across include Europe, the Americas, MEA or Middle East and Africa and Asia Pacific or APAC.
North America will be positioned in the lead over the review period, remarks MRFR, considering the fast adoption rate of modern medical technologies and the soaring number of companies specializing in drug development. Also, the surge in FDA approvals is encouraging players to focus even more on extensive R&D of highly advanced drugs and other treatment lines, which is bound to favor the bleeding disorders treatment market in the ensuing years.
Studies confirm that close to 149,764 people in Europe had hemophilia A and nearly 10,811 of the overall population in the region were diagnosed with platelet disorders in 2016. These statistics indicate the significant growth potential of the bleeding disorders treatment market, as a result of which the region is touted to secure the second position in the following years. Other encouraging factors include the increase in research spending, technical innovations and the general fall in human health across the region. The enhanced need for efficient and advanced therapies and drugs for treating hemophilia also push the market expansion rate in the region.
Leading Firms
Top companies in the global market are Ferring Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Shire Plc, BDI Pharma, Octapharma, Novo Nordisk A/S, Bayer Pharmaceuticals, to name a few.
Latest Developments
October 2020
Bayer AG has acquired Asklepios BioPharmaceutical Inc., a reputed biopharmaceutical firm in the US, known for its specialization in research and development as well as manufacturing of advanced gene therapies with respect to multiple therapeutic areas. This acquisition is expected to drive Bayer AG’s gene and cell therapy platform to facilitate efficient treatments for patients with diseases like hemophilia.
Browse more details of the Report @ https://www.marketresearchfuture.com/reports/bleeding-disorders-treatment-market-6592
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment